2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - R02-R05
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

355 Mediator complex tail module subunit MED24 is a selective dependency in acute myeloid leukemia

Ran Xu, PhD, Lumeng Jia2, Timothy Guanci3, Qingyu Luo, MD, PhD4, Xiaoliang Yu5, Hayden Luke Bell6, Amanda Fortune7, Karley Whalen8, Stuart Orkin, MD9, Andrew A. Lane, MD, PhD10
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber/Boston Children’s Hospital Cancer and Blood Disorder Center, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber/Boston Children’s Hospital Cancer and Blood Disorder Center, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States, Howard Hughes Medical Institute, Harvard Medical School, Boston, United States
10 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Acute myeloid leukemia (AML) is sustained by transcriptional programs with aberrantly activated enhancers that promote proliferation and block myeloid differentiation. These programs are difficult to target as the core transcriptional machinery is broadly essential. Mediator, a ~30-subunit coactivator complex, bridges enhancer-bound transcription factors to RNA polymerase and concentrates at lineage-related super-enhancers (SEs). Its head and middle modules form the essential core, whereas the tail and kinase modules play regulatory roles. Whether individual Mediator subunits are selectively required in AML but not normal hematopoiesis is largely unknown.

To identify selective AML dependencies, we first performed genome-wide CRISPR interference (CRISPRi) in CAL-1 myeloid leukemia cells, which defined 327 dependency genes. Then, we performed secondary RNAi validation in four AML models of diverse genotypes (THP-1, U937, MV4-11, P31/FUJ) using 10 shRNAs/gene, each with a C911 control (bases 9-11 complemented) that abolishes on-target activity but preserves the off-target seed sequence. MED24, a Mediator tail subunit, was the top dependency across all five lines. Unlike the pan-essential Mediator core, in DepMap MED24 was selectively required in leukemia over other cancers, independent of genotype and MED24 expression.

We next validated MED24 dependency. Two independent shRNAs impaired proliferation across five AML lines (THP-1, U937, MV4-11, P31/FUJ, CAL-1). The effect was rescued by re-expression of an shRNA-resistant MED24 cDNA. MED24 loss induced myelomonocytic differentiation, cell cycle arrest, and/or apoptosis. Doxycycline-inducible CRISPR deletion of MED24 with two independent sgRNAs prolonged survival in a TP53-mutant AML patient-derived xenograft in vivo (median 49.5 versus 34 days; log-rank p<0.001).

MED24 dependence was selective for AML. Two lymphoma lines (L82, KI-JK) expressing MED24 at levels comparable to sensitive AML showed no dependency. RNA-seq after inducible knockdown in AML revealed downregulation of MYC and E2F programs and upregulation of myeloid differentiation signatures, whereas lymphoma gene expression was unaffected despite comparable MED24 loss. Most importantly, MED24 depletion markedly reduced colony formation by primary AML bone marrow samples but spared myeloid and erythroid colony formation by normal CD34+ progenitors.

To resolve MED24’s acute effects, we knocked dTAG-MED24-FLAG into its endogenous locus in THP-1 and U937. Degrader-induced depletion recapitulated the growth defect without altering other Mediator subunits. By ChIP-seq, MED24 occupied typical enhancers and >90% of SEs, co-localized with MED6 (Mediator core), with peaks enriched for CEBP motifs at myeloid differentiation genes. Acute degradation (6h) preferentially reduced H3K27ac at Mediator-bound SEs, with downregulation of the corresponding genes (e.g., MYB, MPO, CITED2) and pronounced H3K27ac loss at the MYB super-enhancer and 8q24 MYC blood-enhancer cluster.

To test if MED24 selectively supports AML enhancers, we leveraged independent SE data (SEdb3.0) and H3K27ac profiles from AML and normal HSPCs to classify super-enhancers as AML- or HSPC-specific. Cross-referencing with our functionally defined MED24-sensitive SEs, acute (6h) dTAG MED24 degradation preferentially reduced H3K27ac at AML-specific SEs over HSPC-specific SEs (Mann-Whitney p=0.013). Chronic shMED24 knockdown showed the same selectivity, with AML-specific SEs more likely to be MED24 sensitive than HSPC-specific SEs (25.8% [8/31] vs 4.1% [6/146]; p=0.0005). Thus, MED24 preferentially maintains AML-specific super-enhancer activity, consistent with a leukemia-selective transcriptional dependency.

Finally, Flag-MED24 IP-mass spectrometry in THP-1 cells (MLL-AF9/KMT2A-MLLT3) showed that, beyond Mediator, MED24 associated with MLL-AF9 and the pause-release/elongation machinery (P-TEFb, Super Elongation Complex, 7SK snRNP). Endogenous MED6 IP showed that acute MED24 degradation selectively dissociated the Mediator tail module (MED16/23/24) while preserving the core (head and middle modules).

Together, these data establish MED24 as a Mediator tail subunit that is selectively required in AML, which is an unexpected vulnerability given the general essentiality of Mediator. MED24 sustains AML-specific super-enhancers and the leukemic program while sparing normal hematopoiesis, thus defining a novel lineage-selective target with a potential therapeutic window in AML.

Ran Xu, PhD: No relevant conflicts of interest to declare.